Provided by Tiger Trade Technology Pte. Ltd.

Olema Pharmaceuticals, Inc.

13.67
-0.4500-3.19%
Post-market: 13.41-0.2600-1.90%17:20 EDT
Volume:1.20M
Turnover:16.48M
Market Cap:1.19B
PE:-7.31
High:14.13
Open:13.75
Low:13.34
Close:14.12
52wk High:36.26
52wk Low:2.86
Shares:87.16M
Float Shares:71.89M
Volume Ratio:0.45
T/O Rate:1.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8700
EPS(LYR):-1.8700
ROE:-36.61%
ROA:-21.42%
PB:2.49
PE(LYR):-7.31

Loading ...

Olema Pharmaceuticals Inc. to Participate in Jefferies London Healthcare Conference

Reuters
·
Nov 04, 2025

Olema Pharmaceuticals Announces Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib for Advanced Breast Cancer

Reuters
·
Oct 31, 2025

Promising Outlook for Olema Pharmaceuticals: Buy Rating Driven by Palazestrant’s Potential in Breast Cancer Treatment

TIPRANKS
·
Oct 27, 2025

JPMorgan healthcare analysts hold an analyst/industry conference call

TIPRANKS
·
Oct 23, 2025

Olema Pharmaceuticals Reports Positive Phase 1b/2 Trial Results

TIPRANKS
·
Oct 21, 2025

Olema Pharmaceuticals Shares Fall After Roche's Breast Cancer Data Weighs on Sector

MT Newswires Live
·
Oct 20, 2025

Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Benzinga
·
Oct 20, 2025

Olema Pharmaceuticals Price Target Maintained With a $28.00/Share by HC Wainwright & Co.

Dow Jones
·
Oct 20, 2025

Oppenheimer remains bullish on Olema despite ‘Jekyll and Hyde kinda ESMO’

TIPRANKS
·
Oct 20, 2025

Oppenheimer Remains a Buy on Olema Pharmaceuticals (OLMA)

TIPRANKS
·
Oct 20, 2025

Olema announces updated data on Phase 1b/2 study of palazestrant, ribociclib

TIPRANKS
·
Oct 20, 2025

Olema Reports Promising Phase 1b/2 Data for Palazestrant Plus Ribociclib in Advanced Breast Cancer

Reuters
·
Oct 18, 2025

Olema Oncology Announces New Data From the Phase 1B/2 Trial of Palazestrant Plus Ribociclib in Er+/Her2- Metastatic Breast Cancer at Esmo 2025

THOMSON REUTERS
·
Oct 18, 2025

Guggenheim Initiates Olema Pharmaceuticals at Buy With $20 Price Target

MT Newswires Live
·
Oct 08, 2025

Olema Pharmaceuticals (OLMA) Gets a Buy from Guggenheim

TIPRANKS
·
Oct 08, 2025

Olema Pharmaceuticals Grants Stock Options to New Employees Under 2022 Inducement Plan

Reuters
·
Oct 03, 2025